Skip to main content


06-05-2022 | ADA 2022 | Conference coverage | News

Vitamin B12 monitoring rare despite metformin prescription

Clinicians are only rarely monitoring vitamin B12 levels in people with type 2 diabetes using metformin, research shows.

06-01-2022 | Cardiovascular outcomes | News

No long-term CV benefits seen 2 decades after DPP interventions

People with impaired glucose tolerance who received metformin or intensive lifestyle intervention during the DPP trial show no sign of a significantly reduced cardiovascular disease risk 21 years later, reveal the latest DPPOS results.

05-27-2022 | SGLT2 inhibitors | News

Heart failure benefits seen with first-line SGLT2 inhibition

People who start SGLT2 inhibitors as a first-line diabetes treatment have a reduced risk for heart failure hospitalization relative to those who start metformin and a similar risk for other vascular outcomes, a study shows.

05-13-2022 | Dorzagliatin | News

DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes

People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.

04-11-2022 | Medications | News

Therapeutic inertia increasing in type 2 diabetes

The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.

03-29-2022 | Metformin | News

Paternal metformin exposure linked to increased birth defect risk

The risk for a birth defect may be increased if the father is taking metformin around the time of spermatogenesis, say researchers.

01-10-2022 | COVID-19 | News

COVID-19 vaccination may lead to temporary changes in glucose control

The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.

12-17-2021 | Heart failure | News

Metformin, but not sulfonylurea, may reduce poor outcome risk post HHF

Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.

Related topics